Value
4.4/10data confidence 67%| Component | Sub-score |
|---|---|
| P/S | 7.0 |
| EV/EBITDA | 0.0 |
| p ocf | 3.3 |
| Analyst target | 5.0 |
- ▸P/OCF: 33.1x (FFO proxy — REITs gated off P/E)
AHR · Why this verdict
Why American Healthcare REIT (AHR) is rated SELL
Updated
Model-generated analysis — not investment advice. Not a registered investment advisor. Past performance does not guarantee future results. How we score · Editorial policy
Show full disclosure ▾Hide full disclosure ▴
About TrendMatrix. TrendMatrix is a publisher of general securities research and market commentary. We publish on a regular schedule. All content is the same for every subscriber in a tier — we do not provide personalized investment advice and we do not take into account any individual subscriber's financial situation, investment objectives, risk tolerance, tax situation, or holdings.
Not investment advice. TrendMatrix is not a registered investment adviser. Our content is for informational and educational purposes only. Consult your own licensed investment adviser, broker, or tax professional before making any investment decision.
Conflicts and positions. People who build TrendMatrix, or entities they control, may hold positions, long or short, in securities it covers, and may trade them at any time. Positions are not disclosed individually. Verdicts are generated by an automated model applied by the same rules to every covered stock, and are not adjusted for any position held by the people who build TrendMatrix. We do not accept payment from issuers for coverage.
No paid promotion. TrendMatrix does not accept payment from any issuer, broker, or third party in exchange for coverage of any security.
No fiduciary duty. No fiduciary, advisory, or agency relationship is created between you and TrendMatrix by reading our content or subscribing to our service.
Performance. Past performance is not indicative of future results. Performance figures reflect the published model only and do not reflect any individual subscriber's actual results.
VerdictSELL
Overall score5.9/10
ConfidenceMEDIUM
MacroRISK_OFF
TrendMatrix Research · core thesis
Engine thesis — one sentence
American Healthcare REIT shows 25% growth, 328% cash conversion and positive momentum, but 55.5% operator concentration, 17% short interest and only 7.1% upside to the analyst target limit the case.
Falsifiable statement — pillar-level invalidators below. Engine-derived; not personalized advice.
Thesis pillars
| Pillar | Expectation | Trend |
|---|---|---|
The REIT is growing 25% YoY with excellent 328% FCF-to-net-income conversion and a 7/9 Piotroski score. Growth breakdown | Growth stays above 15% YoY with FCF conversion above 150%. | →Stable |
| CounterAcquisition-driven growth can slow, and REIT cash conversion is boosted by depreciation add-backs. | ||
Trilogy Manager accounts for 55.5% of counterparty exposure, tying results to one operator. Bear case | The Trilogy share declines as other operators grow. | ↓Deteriorating |
| CounterTrouble at a single operator would hit more than half of the portfolio income. | ||
Price is above the 200-day average with rising on-balance volume and a golden-cross breakout, giving a momentum score of 7.1. Momentum breakdown | Price stays above the 200-day average and momentum stays above 5.5. | ↑Improving |
| CounterWith a 17% short interest and an elevated put/call ratio of 7.25, traders are positioned for a reversal. | ||
The $57.32 analyst target offers 7.1% upside against 8.0% downside from $53.52, a reward-to-risk of 0.89. Estimated upside | Analyst targets rise above $60 within 12 months. | →Stable |
| CounterDownside exceeds upside, and a P/OCF of 32.2x is expensive for a REIT. | ||
Earnings have mostly landed in line with expectations, with one 74.9% beat in November 2025 and a 18.2% average surprise, and results are due in 4 days. Avg surprise pct | The 2026-11-05 report lands at or above consensus. | →Stable |
| CounterThree of four quarters were in-line results of roughly $0.14 to $0.15, so the average is skewed by one large beat. | ||
The REIT is growing 25% YoY with excellent 328% FCF-to-net-income conversion and a 7/9 Piotroski score.
→StableGrowth breakdown
- Expectation
- Growth stays above 15% YoY with FCF conversion above 150%.
CounterAcquisition-driven growth can slow, and REIT cash conversion is boosted by depreciation add-backs.
Trilogy Manager accounts for 55.5% of counterparty exposure, tying results to one operator.
↓DeterioratingBear case
- Expectation
- The Trilogy share declines as other operators grow.
CounterTrouble at a single operator would hit more than half of the portfolio income.
Price is above the 200-day average with rising on-balance volume and a golden-cross breakout, giving a momentum score of 7.1.
↑ImprovingMomentum breakdown
- Expectation
- Price stays above the 200-day average and momentum stays above 5.5.
CounterWith a 17% short interest and an elevated put/call ratio of 7.25, traders are positioned for a reversal.
The $57.32 analyst target offers 7.1% upside against 8.0% downside from $53.52, a reward-to-risk of 0.89.
→StableEstimated upside
- Expectation
- Analyst targets rise above $60 within 12 months.
CounterDownside exceeds upside, and a P/OCF of 32.2x is expensive for a REIT.
Earnings have mostly landed in line with expectations, with one 74.9% beat in November 2025 and a 18.2% average surprise, and results are due in 4 days.
→StableAvg surprise pct
- Expectation
- The 2026-11-05 report lands at or above consensus.
CounterThree of four quarters were in-line results of roughly $0.14 to $0.15, so the average is skewed by one large beat.
Per-dimension breakdown
Quality
4.0/10data confidence 100%| Component | Sub-score |
|---|---|
| ROE | 1.3 |
| ROA | 1.4 |
| Gross margin | 0.0 |
| Op margin | 2.7 |
| Net margin | 2.4 |
| Current ratio | 4.9 |
| FCF quality | 10.0 |
| Moat | 5.6 |
| Piotroski F | 7.8 |
- ▸Excellent cash conversion: 328% FCF/NI
- ▸Strong Piotroski F-Score: 7/9
Growth
9.3/10data confidence 67%| Component | Sub-score |
|---|---|
| Rev growth | 8.7 |
| EPS growth | 10.0 |
- ▸Strong growth: 25% YoY
Momentum
7.6/10data confidence 100%| Component | Sub-score |
|---|---|
| RSI | 5.5 |
| MACD | 10.0 |
| OBV | 10.0 |
| MA position | 9.0 |
| Volume | 3.5 |
- ▸Volume accumulation (rising OBV)
- ▸Above 200-day MA
Sentiment
7.2/10data confidence 100%| Component | Sub-score |
|---|---|
| Analyst rating | 8.7 |
| Price target | 7.2 |
| erm sentiment | 5.0 |
Insider
5.0/10data confidence 75%| Component | Sub-score |
|---|---|
| materiality | 5.0 |
| holder change | 5.0 |
| notable moves | 5.0 |
- ▸Negligible insider selling — $188,870 (0.002% of mkt cap)
Peer rank
5.5/10data confidence 80%| Component | Sub-score |
|---|---|
| value rank | 3.8 |
| quality rank | 3.7 |
| growth rank | 6.0 |
- ▸Conservative debt levels
Technical
3.3/10data confidence 100%| Component | Sub-score |
|---|---|
| bollinger | 0.7 |
| support resistance | 0.4 |
| 52w position | 8.8 |
Risk (lower is worse)
3.9/10data confidence 100%| Component | Sub-score |
|---|---|
| short interest | 1.8 |
| days to cover | 0.4 |
| volatility | 5.5 |
| put call | 0.0 |
| implied vol | 4.1 |
| max pain risk | 3.0 |
| beta | 8.3 |
| debt equity | 8.3 |
- ▸High short interest justified: 17%
- ▸Elevated put/call: 6.00
- ▸Above max pain $45
- ▸Concentration risks: 1 HIGH (10-K Item 1A — sized via position_sizing, validated via buy_confidence)
Catalyst
6.8/10data confidence 100%| Component | Sub-score |
|---|---|
| erm | 5.0 |
| earnings history | 10.0 |
| earnings timing | 5.0 |
| surprise avg | 10.0 |
| dividend safety | 4.2 |
- ▸Earnings in 1 day
How the verdict was assembled
Engine trigger
Multiple concerning factors. Consider reducing position.
Engine technical detail
verdict_path:
L4:PATH_F_SELLPassed (5)
- MOMENTUM:7.6>=5.5
- INSIDER:OK
- NEWS_EVENTS:NONE_RECENT
- SEMI_CYCLE_PEAK:CLEAR
- MATERIALS_CYCLE_PEAK:CLEAR
Failed (2)
- ASYMMETRY:0.4<1.5@spot
- EARNINGS_PROXIMITY:1d<=7d
Warning (1)
- 8K_CSUITE_CHANGE:5.02 (officer departure/appointment)
Reward-to-Risk
0.42
Upside
+4.3%
Downside
10.3%
Sizing output
AVOID
SetupBreakout — Golden cross, above all MAs, RSI 60, MACD bullish
EdgeNo clear edge — No clear edge identified
SuitabilityModerate — Balanced profile
Investment implication
The F-path SELL output reflects an overall score of 4.2 below the 5.6 soft trigger — multiple weakening dimensions accumulated rather than a single hard-floor breach. The strongest dimension ( Growth at 9.3) was not enough to lift the adjusted overall above the threshold. Co-occurring failed gates ( ASYMMETRY:0.4<1.5@spot, EARNINGS_PROXIMITY:1d<=7d) reinforce the read. Current asymmetry R:R is 0.42 — supplementary context, not the trigger for this path.
The strongest dimensions are Growth at 9.3, Momentum at 7.6, and Sentiment at 7.2; the weakest are Technical at 3.3, Risk (lower is worse) at 3.9, and Quality at 4.0. The V9 engine flagged 2 failed gates with 1 warning, producing an asymmetric reward-to-risk of 0.42 and an engine sizing output of AVOID.
What would invalidate the thesis
Falsifying conditions — when triggered, the corresponding pillar's thesis is invalidated.
- P1Strong Growth Cash Conversion
Trip ifRevenue growth falls below 10% YoY for 2 consecutive quarters.
- P2Trilogy Manager Concentration
Trip ifTrilogy Manager share exceeds 65% from the current 55.5%.
- P3Positive Momentum Breakout
Trip ifPrice falls below the 200-day moving average for 2 consecutive weeks.
- P4Thin Upside Negative Skew
Trip ifPrice falls below the $50.54 stop-loss level.
- P5Earnings In Line With Consensus
Trip ifQuarterly EPS falls below $0.12 from the recent $0.15.